Sertraline
- Generic Name
- Sertraline
- Brand Names
- Zoloft
- Drug Type
- Small Molecule
- Chemical Formula
- C17H17Cl2N
- CAS Number
- 79617-96-2
- Unique Ingredient Identifier
- QUC7NX6WMB
- Background
Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.
Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.
- Indication
Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.
- Associated Conditions
- Binge Eating Disorder (BED), Bulimia Nervosa, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD)
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 183
- Registration Number
- NCT05537584
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
Sertraline Effect in Uremic Pruritis
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 60
- Registration Number
- NCT05341843
- Locations
- 🇪🇬
Faculty of Medicine, Aexandria University, Alexandria, Egypt
Personalized Sertraline Dosing in Patients With Depression
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- University of Belgrade
- Target Recruit Count
- 148
- Registration Number
- NCT05210153
- Locations
- 🇷🇸
Institute of Mental Health, Belgrade, Serbia
🇷🇸Clinical Centre of Serbia, Belgrade, Serbia
🇷🇸Military Medical Academy, Belgrade, Serbia
Virtual Reality Exposure Therapy in the Intensive Treatment of Social Anxiety Disorder
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 200
- Registration Number
- NCT04977544
- Locations
- 🇨🇳
The Fourth Affiliated Hospital of Zhejiang University Medical College, Yiwu, Zhejiang, China
Sertraline Combined With Fluvoxamine in the Treatment of Refractory Obsessive-compulsive Disorder
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 400
- Registration Number
- NCT04963257
- Locations
- 🇨🇳
The Fourth Affiliated Hospital of Zhejiang University Medical College, Yiwu, Zhejiang, China
NMDA Modulation in Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- China Medical University Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT04637620
- Locations
- 🇨🇳
Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan
Pragmatic Trial of Obsessive-compulsive Disorder
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 1600
- Registration Number
- NCT04539951
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China
A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 440
- Registration Number
- NCT04476030
- Locations
- 🇺🇸
Sage Investigational Site, Bellevue, Washington, United States
Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea
- Conditions
- Major Depression
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 370212
- Registration Number
- NCT04446039
- Locations
- 🇰🇷
Pfizer, Seoul, Korea, Republic of
Brain Hippocampal Volume Relationship With Anxious Symptoms in Major Depressive Patients
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Target Recruit Count
- 30
- Registration Number
- NCT04430556
- Locations
- 🇲🇽
Hospital Universitario Dr. Jose E. Gonzalez, Monterrey, Nuevo Leon, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.